Trial Profile

A randomized, double-blind phase 1 study assessing pharmacodynamic effects for ALTO-101

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALTO 101 (Primary) ; ALTO 101 (Primary)
Indications Neurodegenerative disorders; Psychiatric disorders
Focus First in man; Pharmacodynamics

Most Recent Events

09 May 2024 According to an Alto Neuroscience media release, company announced upcoming data presentations that highlight the companys precision psychiatry pipeline and biomarker based analyses at the Society of Biological Psychiatry (SOBP) and American Society of Clinical Psychopharmacology (ASCP) Annual Meetings, to take place May 9 to 11 in Austin, TX, and May 28 to 31 in Miami Beach, FL, respectively.
23 Apr 2024 Results presented in the Alto Neuroscience Media Release
22 Mar 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com